- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04724642
COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency
Efficacy and Safety of COVID-19 Vaccine in Patients After Allogeneic Hamatopoietic Cell Transplantation, CAR-T Therapy and With Primary Immune Deficiency - a Post Marketing Prospective Cohort Study
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19).
The purpose of the study is to confirm the accepted hypothesis from the recommendations of The European Society for Blood and Marrow Transplantation, that the vaccine for COVID-19 is safe and has good efficacy in immunocompromised patients after a bone marrow transplant from a donor / cellular therapy.
Study Overview
Status
Detailed Description
The study population will be allogeneic bone marrow transplant patients and those who have received CART therapy - immunocompromised patients who are vaccinated with COVID-19 in a commercial preparation, regardless of the study.
The following procedures are routinely performed before receiving the vaccine in the bone marrow transplant unit -
- Blood count and lymphocyte subgroup counts before vaccination (up to 48 hours before vaccination).
- Evaluation of GVHD activity and accompanying toxicity.
- Receipt of a letter confirming the vaccination to the HMO.
- One-week follow-up after vaccination including blood count, complete chemistry, GVHD evaluation, and review of adverse reactions that may be vaccine-related.
- Referral for a second dose of the vaccine.
- One week follow-up after vaccination including blood count, complete chemistry, GVHD evaluation, review of side effects that may be vaccine related.
The following procedures are performed only as part of the study -
Serology test (IgG AntiS) two weeks after the second dose of the vaccine to test the effectiveness of the vaccine.
Cell separation two weeks after the second vaccination and execution -
- ELISpot test to test for the release of interferon gamma in response to the stimulation of cells separated with the SARS-COV-2 virus peptides (stimulation with S peptides to evaluate vaccine response, and stimulation with M peptides as a control).
All data collected in the study will be typed into Excel and analyzed using SPSS version 25.0. Continuous data will be described using averages and standard deviations, and categorical data will be described using prevalence and percentages.
The distribution of the continuous variables will be presented using an outline graph and will be examined using the Kolmogorov Smirnov test.
An attempt will be made to perform subgroup analysis (depending on the frequency of the groups in the sample) for the patient group:
Patients after bone marrow transplantation with acute GVHD Patients after bone marrow transplantation with chronic GVHD Patients after bone marrow transplantation without immunosuppressive therapy Patients after Cell Therapy (CART) Patients lack primary immunization
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Ron Ram, Prof.
- Phone Number: 3782 972-3-6973782
- Email: ronr@tlvmc.gov.il
Study Locations
-
-
-
Tel-Aviv, Israel, 6423906
- Recruiting
- Tel-Aviv Sourasky Medical Center
-
Contact:
- Ron Ram, Prof.
- Phone Number: 3782 972-3-6973782
- Email: ronr@tlvmc.gov.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 18 and over
- Patient sex - male and female
- Bone marrow transplant from a donor (sibling or unrelated) or after cell therapy (CART) at least 3 months before vaccination.
- Patients with primary immunodeficiency syndrome.
- Patients who are able to sign an informed consent form
Exclusion Criteria:
- Patients under 18 years of age
- Patients who are unable to give informed consent
- Patients with acute GVHD who require steroid therapy above 0.5 mg / kg or who have been diagnosed in the last month.
- Patients with chronic GVHD who require steroid therapy above 0.5 mg / kg
- Patients treated with rituximab / immunoglobulins / mesenchymal cells during the last month.
- Patients whose disease is not completely cured and receive dedicated treatment for the disease.
- Patients receiving maintenance treatment for the underlying disease (excluding TKIs such as sorfenib, midostaurin, guiltritinib or cranolinib).
- Patients who have previously had COVID19.
- Patients with severe allergy to one of the vaccine components.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of side effects in patients
Time Frame: 10 weeks counting since first vaccination is initiated.
|
Incidence of side effects in patients post allogeneic bone marrow transplantation after COVID-19 vaccination
|
10 weeks counting since first vaccination is initiated.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of severe adverse reactions
Time Frame: 10 weeks counting since first vaccination is initiated.
|
|
10 weeks counting since first vaccination is initiated.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ron Ram, Prof, Tel-Aviv Sourasky Medical Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1067-20
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Immunodeficiency
-
CSL BehringCompletedPrimary Immunodeficiency (PID)Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
-
CSL LimitedCompleted
-
CSL BehringCompleted
-
ShireCompleted
-
Ottawa Hospital Research InstituteOctapharmaUnknownPrimary Immunodeficiency Disease | Secondary ImmunodeficiencyCanada
-
OctapharmaCompletedPrimary Immunodeficiency (PID)France
-
CHU de ReimsUnknown
-
National Cancer Institute (NCI)RecruitingImmune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune LymphoproliferativeUnited States
-
OctapharmaCompleted
-
Assiut UniversityCompleted